Media coverage about Novo Nordisk (NYSE:NVO) has trended somewhat positive recently, Accern reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Novo Nordisk earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.7645704642315 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
NVO has been the subject of several research analyst reports. Zacks Investment Research downgraded Novo Nordisk from a “hold” rating to a “sell” rating in a research report on Tuesday, March 27th. Deutsche Bank reiterated a “buy” rating on shares of Novo Nordisk in a research report on Monday, January 8th. Finally, JPMorgan Chase upgraded Novo Nordisk from an “underweight” rating to a “neutral” rating in a research report on Friday, December 29th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $64.00.
NVO traded down $0.25 during trading on Friday, hitting $48.57. The company’s stock had a trading volume of 909,946 shares, compared to its average volume of 1,479,658. Novo Nordisk has a 12 month low of $35.10 and a 12 month high of $58.37. The company has a market cap of $119,366.34, a price-to-earnings ratio of 20.76, a PEG ratio of 2.39 and a beta of 0.67.
Novo Nordisk declared that its Board of Directors has initiated a stock buyback plan on Thursday, February 1st that allows the company to repurchase shares. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.
The firm also recently disclosed a special dividend, which was paid on Tuesday, April 3rd. Shareholders of record on Monday, March 26th were given a $0.8117 dividend. The ex-dividend date was Friday, March 23rd. This represents a yield of 0.96%. Novo Nordisk’s payout ratio is 38.89%.
About Novo Nordisk
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.
Receive News & Ratings for Novo Nordisk Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk and related companies with MarketBeat.com's FREE daily email newsletter.